End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Authors
Keywords
-
Journal
Future Oncology
Volume 13, Issue 13, Pages 1181-1193
Publisher
Future Medicine Ltd
Online
2017-04-11
DOI
10.2217/fon-2016-0504
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology
- (2015) A. Hoos et al. CLINICAL CANCER RESEARCH
- Lenalidomide Dose Modifications and Associated Patient Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)
- (2015) S. Usmani et al. Clinical Lymphoma Myeloma & Leukemia
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- Curing myeloma at last: defining criteria and providing the evidence
- (2014) B. Barlogie et al. BLOOD
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
- (2013) G. Gahrton et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
- (2013) Emmanuel Clave et al. LEUKEMIA & LYMPHOMA
- Improved survival modeling in cancer research using a reduced piecewise exponential approach
- (2013) Gang Han et al. STATISTICS IN MEDICINE
- Allogeneic transplantation in multiple myeloma
- (2013) Gösta Gahrton et al. Expert Review of Hematology
- Statistical issues and challenges in immuno-oncology
- (2013) Tai-Tsang Chen Journal for ImmunoTherapy of Cancer
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
- (2012) Hagop Kantarjian et al. CANCER
- Cure Models as a Useful Statistical Tool for Analyzing Survival
- (2012) M. Othus et al. CLINICAL CANCER RESEARCH
- Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma
- (2012) Kan-ichi Iwama et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
- (2012) S Z Usmani et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immuno-oncology framework
- (2012) Axel Hoos et al. OncoImmunology
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- A methodological framework to enhance the clinical success of cancer immunotherapy
- (2011) Axel Hoos et al. NATURE BIOTECHNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
- (2010) Jean-Luc Harousseau Clinical Lymphoma Myeloma & Leukemia
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
- (2010) Marc Buyse STATISTICS IN MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN- 2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
- (2009) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
- (2009) Benjamin D. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Reformulating the hazard ratio to enhance communication with clinical investigators
- (2008) Barry K Moser et al. Clinical Trials
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots
- (2008) P. Royston et al. JNCI-Journal of the National Cancer Institute
- Weibull prediction of event times in clinical trials
- (2007) Gui-shuang Ying et al. PHARMACEUTICAL STATISTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started